Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study

F Cosman, C Cooper, Y Wang, B Mitlak, S Varughese, S A Williams, F Cosman, C Cooper, Y Wang, B Mitlak, S Varughese, S A Williams

Abstract

Real-world evidence on the comparative effectiveness and safety of abaloparatide versus teriparatide in women with osteoporosis may help inform treatment decisions. Following 18 months of treatment, abaloparatide was comparable to teriparatide for prevention of nonvertebral fractures, resulted in a 22% risk reduction for hip fractures, and demonstrated similar cardiovascular safety. Osteoporotic fracture risk can be reduced with anabolic or antiresorptive medications. In addition to efficacy and safety data from controlled clinical trials, real-world evidence on comparative effectiveness and safety may help inform treatment decisions.

Introduction: The real-world effectiveness of abaloparatide versus teriparatide on nonvertebral fracture (NVF) incidence and cardiovascular safety during the 19-month period after treatment initiation were evaluated (NCT04974723).

Methods: Anonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy. Most were enrolled in commercial and Medicare health plans. Index was the date of the initial prescription dispensed during the identification period. In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model.

Results: Propensity score matching yielded 11,616 patients per cohort. Overall median age (interquartile range) was 67 (61, 75) years, and 25.6% had a fracture history. Over 19 months, 335 patients on abaloparatide and 375 on teriparatide had a NVF (hazard ratio [95% confidence interval]: 0.89 [0.77, 1.03]), and 121 and 154 patients, respectively, had a hip fracture [HR (95% CI): 0.78 (0.62, 1.00)]. The MACE and MACE + HF rates were similar between cohorts.

Conclusions: Following 18 months of treatment, abaloparatide was comparable to teriparatide for prevention of NVF and similar cardiovascular safety was demonstrated between cohorts.

Keywords: Osteoporosis; abaloparatide; administrative claims; comparative effectiveness; nonvertebral fractures; teriparatide.

Conflict of interest statement

The authors declare that they have no personal conflicts.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study design and timeline
Fig. 2
Fig. 2
Distribution of the propensity score before and after propensity score matching
Fig. 3
Fig. 3
a) Time to event of nonvertebral fractures. b) Time to event of hip fractures. CI, confidence interval. aPatients at risk include all patients regardless of when treatment was discontinued, except those who had a fracture event or died

References

    1. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. doi: 10.1007/s00198-014-2794-2.
    1. Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United Sates based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–2526. doi: 10.1002/jbmr.2269.
    1. International Osteoporosis Foundation. Key Statistics for North America. . Accessed 29 March 2022.
    1. Osteoporosis Fast Facts. National Osteoporosis Foundation. . Accessed 29 March 2022.
    1. Gold T, Williams SA, Weiss RJ, et al. Impact of fractures on quality of life in patients with osteoporosis: a US cross-sectional survey. J Drug Assess. 2019;8(1):175–183. doi: 10.1080/21556660.2019.1677674.
    1. Singer A, Exuzides A, Spangler L, et al. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc. 2015;90(1):53–62. doi: 10.1016/j.mayocp.2014.09.011.
    1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–475. doi: 10.1359/jbmr.061113.
    1. Williams SA, Daigle SG, Weiss R, et al. Economic Burden of US Osteoporotic Fractures in the US Medicare Population. Ann Pharmacother. 2021 doi: 10.1177/1060028020970518.
    1. Bilezikian JP, Hattersley G, Fitzpatrick LA, et al. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporos Int. 2018;29(2):323–328. doi: 10.1007/s00198-017-4304-9.
    1. Forteo (2021) Package insert. Lilly USA LLC.
    1. Tymlos (2021) Package insert. Radius Health Inc.
    1. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinol. 2016;157(1):141–149. doi: 10.1210/en.2015-1726.
    1. Miller PD, Hattersley G, Riis BJ, et al. Effects of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Randomized Clinical Trial. JAMA. 2016;316(7):722–733. doi: 10.1001/jama.2016.11136.
    1. Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949–2957. doi: 10.1210/jc.2018-00163.
    1. Reginster J-Y, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019;30(7):1465–1473. doi: 10.1007/s00198-019-04947-2.
    1. Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104(5):1623–1630. doi: 10.1210/jc.2019-00192.
    1. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622. doi: 10.1210/jc.2019-00221.
    1. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther. 2018;35(11):1763–1774. doi: 10.1007/s12325-018-0805-y.
    1. Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women A meta-analysis. Thromb Haemost. 2008;99(2):338–342. doi: 10.1160/TH07-07-0468.
    1. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686–696. doi: 10.1056/NEJMoa0808692.
    1. McClung MR, O'Donoghue ML, Papapoulos SE, et al. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 2019;7(12):899–911. doi: 10.1016/S2213-8587(19)30346-8.
    1. Evenity (2019) Package insert. Amgen Inc.
    1. Cosman F, Peterson LR, Towler DA, Mitlak B, Wang Y, Cummings SR. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial. J Clin Endocrinol Metab. 2020;105(11):3384–3395. doi: 10.1210/clinem/dgaa450.
    1. Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005;20(11):1912–1920. doi: 10.1359/:JBoneMinerRes.2006Feb;21(2):352.
    1. Symphony Health. . Accessed 29 March 2022.
    1. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150–161. doi: 10.1002/pst.433.
    1. Ho DE, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. J Stat Softw. 2011;42(8):1–28. doi: 10.18637/jss.v042.i08.
    1. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following an acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54:387–398. doi: 10.1016/s0895-4356(00)00321-8.
    1. Wright NC, Daigle SG, Melton ME, Delzell ES, Balasubramanian A, Curtis JR. The Design and Validation of a New Algorithm to Identify Incident Fractures in Administrative Claims Data. J Bone Miner Res. 2019;34(10):1798–1807. doi: 10.1002/jbmr.3807.
    1. Xie F, Colantonio LD, Curtis JR, et al. Development of algorithms for identifying fatal cardiovascular disease in Medicare claims. Pharmacoepidemiol Drug Saf. 2018;27(7):740–750. doi: 10.1002/pds.4421.
    1. Ritchey MD, Loustalot F, Wall HK, et al. Million Hearts: Description of the National Surveillance and Modeling Methodology Used to Monitor the Number of Cardiovascular Events Prevented During 2012–2016. J Am Heart Assoc. 2017;6(5):e006021. doi: 10.1161/JAHA.117.006021.
    1. FDA mini-sentinel CV events. FDA's Sentinal System, US FDA.
    1. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. doi: 10.1056/NEJM200105103441904.
    1. Silverman S, Langdahl BL, Fujiwara S, et al. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies. Calcif Tissue Int. 2019;104(2):193–200. doi: 10.1007/s00223-018-0485-2.
    1. Winzenrieth R, Humbert L, Boxberger JI, Weiss RJ, Wang Y, Kostenuik P (2021) Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women with Postmenopausal Osteoporosis. J Clin Densitom. S1094–6950(21)00098–6. Epub ahead of print. 10.1016/j.jocd.2021.11.007.
    1. Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss RJ. Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modelling. Osteoporos Int. 2021;32(3):575–583. doi: 10.1007/s00198-020-05806-1.
    1. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone (1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001;16(1):157–165. doi: 10.1359/jbmr.2001.16.1.157.
    1. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18:1932–1941. doi: 10.1359/jbmr.2003.18.11.1932.
    1. MacDonald HM, Nishiyama KK, Hanley DA, Boyd SK. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int. 2011;22:357–362. doi: 10.1007/s00198-010-1226-1.
    1. Sato M, Westmore M, Ma YL, et al. Teriparatide [PTH (1–34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res. 2004;19(4):623–629. doi: 10.1359/JBMR.040112.
    1. Doyle N, Varela A, Haile S, et al. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int. 2018;29(3):685–697. doi: 10.1007/s00198-017-4323-6.
    1. Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G. One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in ovariectomized osteopenic rats without increasing bone resorption. J Bone Miner Res. 2017;32(1):24–33. doi: 10.1002/jbmr.3003.
    1. Samelson EJ, Kiel DP, Broe KE, et al. Metacarpal cortical area and risk of coronary heart disease: the Framingham Study. Am J Epidemiol. 2004;159(6):589–595. doi: 10.1093/aje/kwh080.
    1. European Medicines Agency (2021) Guidelines on registry-based studies. . Accessed 29 March 2022.
    1. US Department of Health and Human Services (2021) Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drugs and Biological Products: Guidance for Industry. . Accessed 29 March 2022.
    1. Berger ML, Sox H, Willke RJ, et al. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033–1039. doi: 10.1002/pds.4297.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅